JMP Securities analyst Jason Butler has reiterated their bullish stance on AQST stock, giving a Buy rating on March 3.
Jason Butler’s rating is based on several key factors. Aquestive Therapeutics is making significant progress in its regulatory and clinical development, particularly with the Anaphylm NDA submission on track for this quarter. The company is preparing for a potential launch in the first quarter of 2026, demonstrating readiness in commercial activities and a strong financial position with $71.5 million at the end of 2024, which supports its commercialization efforts.
Furthermore, Aquestive is advancing its pipeline development, with plans to initiate a Phase 2a trial for AQST-108 in alopecia areata patients in the second quarter of 2025. The company’s preparations for commercialization, including market access activities and potential international partnerships, further bolster confidence in its ability to launch Anaphylm successfully. These strategic moves, alongside robust clinical data and a clear path to market, underpin Jason Butler’s Buy rating for Aquestive Therapeutics.
In another report released on March 3, Leerink Partners also reiterated a Buy rating on the stock with a $13.00 price target.